Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ASMB
Previous Symbol
CUSIP92282210
Phone317-210-9311
Debt
Debt-to-Equity RatioN/A
Current Ratio16.43
Quick Ratio16.43
Price-To-Earnings
Trailing P/E Ratio-10.24
Forward P/E Ratio-6.29
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.02 million
Price / Sales69.63
Cash FlowN/A
Price / CashN/A
Book Value$9.01 per share
Price / Book2.74
Profitability
EPS (Most Recent Fiscal Year)($2.41)
Net Income$-42,800,000.00
Net Margins-469.91%
Return on Equity-50.63%
Return on Assets-36.02%
Miscellaneous
Employees79
Outstanding Shares25,460,000
Market Cap$628.17 million
OptionableOptionable
Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions
What is Assembly Biosciences' stock symbol?
Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."
How were Assembly Biosciences' earnings last quarter?
Assembly Biosciences Inc (NASDAQ:ASMB) announced its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.01) by $0.14. The biopharmaceutical company had revenue of $4.29 million for the quarter, compared to analysts' expectations of $3.21 million. Assembly Biosciences had a negative return on equity of 50.63% and a negative net margin of 469.91%. View Assembly Biosciences' Earnings History.
When is Assembly Biosciences' next earnings date?
What price target have analysts set for ASMB?
4 brokerages have issued 1-year target prices for Assembly Biosciences' stock. Their predictions range from $42.00 to $75.00. On average, they expect Assembly Biosciences' share price to reach $60.25 in the next twelve months. This suggests a possible upside of 144.2% from the stock's current price. View Analyst Price Targets for Assembly Biosciences.
What is the consensus analysts' recommendation for Assembly Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Assembly Biosciences.
Has Assembly Biosciences been receiving favorable news coverage?
Media stories about ASMB stock have trended neutral on Sunday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Assembly Biosciences earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Assembly Biosciences' key competitors?
Some companies that are related to Assembly Biosciences include Ascendis Pharma A/S (ASND), Allakos (ALLK), Blueprint Medicines (BPMC), Myokardia (MYOK), ACADIA Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Prestige Consumer Healthcare (PBH), Endocyte (ECYT) and TESARO (TSRO).
Who are Assembly Biosciences' key executives?
Assembly Biosciences' management team includes the folowing people:
- Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 42)
- Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 46)
- Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 68)
- Mr. Thomas E. Rollins, Exec. Officer (Age 62)
- Mr. David J. Barrett CPA, Strategic Advisor (Age 42)
Who are Assembly Biosciences' major shareholders?
Assembly Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Jennison Associates LLC (9.73%), BlackRock Inc. (7.25%), Janus Henderson Group PLC (3.51%), Victory Capital Management Inc. (2.02%), Emerald Advisers Inc. PA (1.56%) and Emerald Mutual Fund Advisers Trust (1.45%). Company insiders that own Assembly Biosciences stock include Derek A Small, Uri A Lopatin and William R Ringo. View Institutional Ownership Trends for Assembly Biosciences.
Which major investors are selling Assembly Biosciences stock?
ASMB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, TIAA CREF Investment Management LLC, AQR Capital Management LLC, Strs Ohio, Credit Suisse AG, Blair William & Co. IL and WINTON GROUP Ltd. Company insiders that have sold Assembly Biosciences company stock in the last year include Uri A Lopatin and William R Ringo. View Insider Buying and Selling for Assembly Biosciences.
Which major investors are buying Assembly Biosciences stock?
ASMB stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., Franklin Resources Inc., Valeo Financial Advisors LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers Inc. PA, FMR LLC and Sphera Funds Management LTD.. View Insider Buying and Selling for Assembly Biosciences.
How do I buy shares of Assembly Biosciences?
Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Assembly Biosciences' stock price today?
One share of ASMB stock can currently be purchased for approximately $24.67.
How big of a company is Assembly Biosciences?
Assembly Biosciences has a market capitalization of $628.17 million and generates $9.02 million in revenue each year. The biopharmaceutical company earns $-42,800,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Assembly Biosciences employs 79 workers across the globe.
What is Assembly Biosciences' official website?
How can I contact Assembly Biosciences?
Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 317-210-9311 or via email at [email protected]
MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
